Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 1;106(3):496-502.
doi: 10.1016/j.ijrobp.2019.11.013. Epub 2019 Nov 20.

Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation Therapy

Homan Mohammadi  1 , Austin Prince  1 , Nicholas B Figura  1 , Jeffrey S Peacock  1 , Daniel C Fernandez  1 , Michael E Montejo  1 , Hye Sook Chon  2 , Robert M Wenham  2 , Steven A Eschrich  3 , Javier F Torres-Roca  1 , Kamran A Ahmed  4
Affiliations

Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation Therapy

Homan Mohammadi et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: Variability exists in the adjuvant treatment for endometrial cancer (EC) based on surgical pathology and institutional preference. The radiosensitivity index (RSI) is a previously validated multigene expression index that estimates tumor radiosensitivity. We evaluate RSI as a genomic predictor for pelvic failure (PF) in EC patients treated with adjuvant radiation therapy (RT).

Methods and materials: Using our institutional tissue biorepository, we identified EC patients treated between January 1999 and April 2011 with primarily endometrioid histology (n = 176; 86%) who received various adjuvant therapies. The RSI 10-gene signature was calculated for each sample using the previously published algorithm. Radiophenotype was determined using the previously identified cutpoint where RSI ≥ 0.375 denotes radioresistance (RR) and RSI < 0.375 describes radiosensitivity.

Results: A total of 204 patients were identified, of which 83 (41%) were treated with adjuvant RT. Median follow-up was 38.5 months. All patients underwent hysterectomy with bilateral salpingo-oophorectomy with the majority undergoing lymph node dissection (n = 181; 88%). In patients treated with radiation, RR tumors were more likely to experience PF (3-year pelvic control 84% vs 100%; P = .02) with worse PF-free survival (PFFS) (3-year PFFS 65% vs 89%; P = .04). Furthermore, in the patients who did not receive RT, there was no difference in PF (P = .87) or PFFS (P = .57) between the RR/radiosensitive tumors. On multivariable analysis, factors that continued to predict for PF included the RR phenotype (hazard ratio [HR], 12.2; P = .003), lymph node involvement (HR, 4.4; P = .02), and serosal or adnexal involvement (HR, 5.3; P = .01).

Conclusions: On multivariable analysis, RSI was found to be a significant predictor of PF in patients treated with adjuvant RT. We propose using RSI to predict which patients are at higher risk for failing in the pelvis and may be candidates for treatment escalation in the adjuvant setting.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Kaplan-Meier Pelvic Control between RS and RR patients treated with RT
Figure 2:
Figure 2:
Kaplan-Meier Pelvic Control between RS and RR patients treated without RT
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians 2019;69:7–34. - PubMed
    1. Wright JD, Medel NIB, Sehouli J, et al. Contemporary management of endometrial cancer. The Lancet 2012;379:1352–1360. - PubMed
    1. Network NCC. Uterine neoplasms. NCCN Guidelines in Oncology 2019;Version 3.
    1. Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the portec cohorts. Clinical Cancer Research 2016;22:4215. - PubMed
    1. Nout RA, Smit V, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (portec-2): An open-label, non-inferiority, randomised trial. The Lancet 2010;375:816–823. - PubMed

Publication types

MeSH terms